We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

118 hedge funds and large institutions have $256M invested in Lyell Immunopharma in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

42% more capital invested

Capital invested by funds: $180M → $256M (+$76.2M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

11% more funds holding

Funds holding: 106 → 118 (+12)

10% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 30

0.18% more ownership

Funds ownership: 2.44% → 2.62% (+0.18%)

0% more call options, than puts

Call options by funds: $3K | Put options by funds: $3K

Holders
118
Holders Change
+12
Holders Change %
+11.32%
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
25
Increased
33
Reduced
30
Closed
13
Calls
$3K
Puts
$3K
Net Calls
–
Net Calls Change
-$11K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$4.92M
2
Bank of America
Bank of America
North Carolina
+$1.68M
3
BlackRock
BlackRock
New York
+$1.59M
4
Morgan Stanley
Morgan Stanley
New York
+$1.51M
5
ICM
Invenomic Capital Management
Massachusetts
+$1.34M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$5.95M
2
State Street
State Street
Massachusetts
-$5.89M
3
FCMI
Foresite Capital Management IV
California
-$828K
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$625K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$478K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mariner
51
Mariner
Kansas
$223K +$64.1K +1,781 +45%
State of Wisconsin Investment Board
52
State of Wisconsin Investment Board
Wisconsin
$201K -$5.62K -156 -3%
SG Americas Securities
53
SG Americas Securities
New York
$192K +$80.4K +2,234 +82%
CIC
54
Cornercap Investment Counsel
Georgia
$188K – – –
MIM
55
MetLife Investment Management
New Jersey
$179K – – –
AIG
56
American International Group
New York
$167K -$612 -17 -0.4%
Franklin Resources
57
Franklin Resources
California
$161K – – –
ETC
58
Exchange Traded Concepts
Oklahoma
$161K +$37.9K +1,052 +34%
IC
59
IEQ Capital
California
$159K – – –
Citigroup
60
Citigroup
New York
$147K -$212K -5,900 -61%
VOYA Investment Management
61
VOYA Investment Management
Georgia
$142K – – –
Renaissance Technologies
62
Renaissance Technologies
New York
$141K +$131K +3,625 New
Deutsche Bank
63
Deutsche Bank
Germany
$136K -$4.18K -116 -3%
Janus Henderson Group
64
Janus Henderson Group
United Kingdom
$134K -$180 -5 -0.1%
PMEF
65
Point72 Middle East FZE
United Arab Emirates
$134K +$124K +3,443 New
EC
66
EntryPoint Capital
New York
$127K +$118K +3,282 New
Principal Financial Group
67
Principal Financial Group
Iowa
$122K -$9.29K -258 -8%
CSS
68
Cubist Systematic Strategies
Connecticut
$120K +$111K +3,083 New
EAM
69
Erste Asset Management
Austria
$114K – – –
Man Group
70
Man Group
United Kingdom
$105K +$97.6K +2,710 New
Wells Fargo
71
Wells Fargo
California
$104K -$120K -3,334 -56%
Prudential Financial
72
Prudential Financial
New Jersey
$101K – – –
New York State Common Retirement Fund
73
New York State Common Retirement Fund
New York
$99.5K -$612 -17 -0.7%
Royal Bank of Canada
74
Royal Bank of Canada
Ontario, Canada
$99K +$39.5K +1,096 +75%
ECM
75
ExodusPoint Capital Management
New York
$99K +$91.6K +2,545 New
1 2
3
4 5

LYEL Hedge Fund Activity: Q4 2023 in Review

118 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2023, worth a combined $256M — up 42% from $180M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new LYEL positions and 13 closed out — a net gain of 12 holders — while 33 added to existing stakes and 30 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $4.92M. The largest seller was Vanguard Group, cutting an estimated $5.95M.

  • 118 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2023, up from 106 in Q3 2023.
  • Funds reported $256M of Lyell Immunopharma stock for Q4 2023, up 42% quarter-over-quarter.
  • 25 funds opened new Lyell Immunopharma positions in Q4 2023 and 13 closed out, a net change of +12 holders.
  • The largest Lyell Immunopharma buyer in Q4 2023 was Citadel Advisors, an estimated $4.92M added.
  • The largest Lyell Immunopharma seller in Q4 2023 was Vanguard Group, an estimated $5.95M sold.

Based on aggregated 13F filings for Q4 2023.